表紙
市場調査レポート

高トリグリセリド血症;パイプライン分析

High Triglyceridemia - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251527
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
高トリグリセリド血症;パイプライン分析 High Triglyceridemia - Pipeline Review, H2 2015
出版日: 2015年07月31日 ページ情報: 英文 109 Pages
概要

高トリグリセリド血症とは、血液中のトリグリセリド(中性脂肪)の水準が上昇する症状で、糖尿病や肥満、座りがちな生活習慣などが主な発症・悪化要因となっています。主な症状として、上腹中央部・胸部・背部の痛みや、吐き気・嘔吐、呼吸困難、角膜環、黄色板病などが挙げられます。一方で、この疾患が冠動脈疾患(CAD)のリスク要因ともなっています。主な治療薬には、フィブリン酸誘導体やスタチンなどがあります。

当レポートでは、世界各国での高トリグリセリド血症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

高トリグリセリド血症の概要

治療薬の開発

  • 高トリグリセリド血症向けパイプライン製品:概要
  • 高トリグリセリド血症向けパイプライン製品:比較分析

各企業で開発中の高トリグリセリド血症治療薬

大学/研究機関で研究中の高トリグリセリド血症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

高トリグリセリド血症治療薬:開発中の製品の一覧(企業別)

高トリグリセリド血症治療薬:研究中の製品の一覧(大学/研究機関別)

高トリグリセリド血症治療薬の開発に従事している企業

  • Acasti Pharma Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Arisaph Pharmaceuticals, Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • BASF SE
  • Cardax Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • CymaBay Therapeutics, Inc.
  • 第一三共
  • Essentialis, Inc.
  • Isis Pharmaceuticals, Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Michigan Life Therapeutics, LLC
  • Novartis AG
  • Pharmena SA
  • Tekmira Pharmaceuticals Corp.
  • Thetis Pharmaceuticals LLC

高トリグリセリド血症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ALN-AC3
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ALN-ANG
  • ARI-3037MO
  • AS-1708727
  • ベザフィブラートER(持続放出)
  • BioE-1115
  • CAT-2003
  • CDX-085
  • ジアゾキシドCR(調整放出)
  • DS-8312
  • icosabutate
  • ISIS-APOCIIILRx
  • MAT-9001
  • MBX-8025
  • NKPL-66
  • ω-3-カルボン酸
  • pradigastat sodium
  • 高トリグリセリド血症向け医薬品
  • 脂質異常症・高トリグリセリド血症向け医薬品
  • TKM-HTG
  • TKMApoC-3
  • TP-101
  • TP-110
  • TRIA-662
  • volanesorsen sodium

高トリグリセリド血症治療薬:パイプライン製品の最新動向

高トリグリセリド血症治療薬:開発が休止状態の製品

高トリグリセリド血症治療薬:開発が中止された製品

高トリグリセリド血症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6859IDB

Summary

Global Markets Direct's, 'High Triglyceridemia - Pipeline Review, H2 2015', provides an overview of the High Triglyceridemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High Triglyceridemia Overview
  • Therapeutics Development
    • Pipeline Products for High Triglyceridemia - Overview
    • Pipeline Products for High Triglyceridemia - Comparative Analysis
  • High Triglyceridemia - Therapeutics under Development by Companies
  • High Triglyceridemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • High Triglyceridemia - Products under Development by Companies
  • High Triglyceridemia - Companies Involved in Therapeutics Development
    • Acasti Pharma Inc.
    • Allergan Plc
    • Alnylam Pharmaceuticals, Inc.
    • Arisaph Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • BASF SE
    • Cardax Pharmaceuticals, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • CymaBay Therapeutics, Inc.
    • Daiichi Sankyo Company, Limited
    • Essentialis, Inc.
    • Isis Pharmaceuticals, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Michigan Life Therapeutics, LLC
    • Novartis AG
    • Pharmena SA
    • Tekmira Pharmaceuticals Corp.
    • Thetis Pharmaceuticals LLC
  • High Triglyceridemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-AC3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARI-3037MO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-1708727 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bezafibrate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BioE-1115 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-2003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-085 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diazoxide choline CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DS-8312 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icosabutate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-APOCIIILRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAT-9001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKPL-66 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omega-3-carboxylic acids - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pradigastat sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hypertriglyceridaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hypertriglyceridemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-HTG - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKMApoC-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRIA-662 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • volanesorsen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • High Triglyceridemia - Recent Pipeline Updates
  • High Triglyceridemia - Dormant Projects
  • High Triglyceridemia - Discontinued Products
  • High Triglyceridemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
      • Mar 25, 2015: Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
      • Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial
      • Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results
      • Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
      • Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014
      • Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
      • May 06, 2014: FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
      • Mar 31, 2014: Catabasis to Present CAT-2003 Data at the American College of Cardiology's 63rd Annual Scientific Session
      • Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for High Triglyceridemia, H2 2015
  • Number of Products under Development for High Triglyceridemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • High Triglyceridemia - Pipeline by Acasti Pharma Inc., H2 2015
  • High Triglyceridemia - Pipeline by Allergan Plc, H2 2015
  • High Triglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Astellas Pharma Inc., H2 2015
  • High Triglyceridemia - Pipeline by AstraZeneca Plc, H2 2015
  • High Triglyceridemia - Pipeline by BASF SE, H2 2015
  • High Triglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
  • High Triglyceridemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • High Triglyceridemia - Pipeline by Essentialis, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
  • High Triglyceridemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
  • High Triglyceridemia - Pipeline by Michigan Life Therapeutics, LLC, H2 2015
  • High Triglyceridemia - Pipeline by Novartis AG, H2 2015
  • High Triglyceridemia - Pipeline by Pharmena SA, H2 2015
  • High Triglyceridemia - Pipeline by Tekmira Pharmaceuticals Corp., H2 2015
  • High Triglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • High Triglyceridemia Therapeutics - Recent Pipeline Updates, H2 2015
  • High Triglyceridemia - Dormant Projects, H2 2015
  • High Triglyceridemia - Dormant Projects (Contd..1), H2 2015
  • High Triglyceridemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for High Triglyceridemia, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top